Baricitinib as potential treatment for 2019-nCoV acute respiratory disease

Peter J. Richardson; Ivan Griffin; Catherine Tucker; D. Casey Smith; Olly Oechsle; Anne M. Phelan; Michael J. Rawling; Edward Savory; Justin Stebbing

doi:10.1016/s0140-6736(20)30304-4

Keywords

LungVirologyMedicineVirusSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)CoronavirusCoronavirus disease 2019 (COVID-19)Computational biologyBiologyInfectious disease (medical specialty)DiseasePathologyInternal medicine

MeSH Terms

AzetidinesBetacoronavirusCOVID-19Coronavirus InfectionsHumansPandemicsPneumoniaViralPurinesPyrazolesSARS-CoV-2SulfonamidesCOVID-19 Drug Treatment

Affiliated Institutions

Related Publications

SARS-CoV-2 vaccines in development

Florian Krammer

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in late 2019 in China and is the causative agent of the coronavirus disease 2019 (COVID-19) pande...

2020 Nature 2193 citations

Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak

Mengyuan Dai , Dianbo Liu , Miao Liu +35 more

Abstract The novel COVID-19 outbreak has affected more than 200 countries and territories as of March 2020. Given that patients with cancer are generally more vulnerable to infe...

2020 Cancer Discovery 1611 citations

The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells

Markus Hoffmann , Hannah Kleine‐Weber , Nadine Krüger +3 more

Abstract The emergence of a novel, highly pathogenic coronavirus, 2019-nCoV, in China, and its rapid national and international spread pose a global health emergency. Coronaviru...

2020 bioRxiv (Cold Spring Harbor Laboratory) 754 citations

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

Timothy Burgess , Jennifer Ferreira , Michelle Green +57 more

Baricitinib plus remdesivir was superior to remdesivir alone in reducing recovery time and accelerating improvement in clinical status among patients with Covid-19, notably amon...

2020 New England Journal of Medicine 1863 citations

Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2

Yadi Zhou , Yuan Hou , Jiayu Shen +3 more

Human coronaviruses (HCoVs), including severe acute respiratory syndrome coronavirus (SARS-CoV) and 2019 novel coronavirus (2019-nCoV, also known as SARS-CoV-2), lead global epi...

2020 Cell Discovery 1664 citations

Publication Info

Year: 2020
Type: letter
Volume: 395
Issue: 10223
Pages: e30-e31
Citations: 1452
Access: Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric

Baricitinib as potential treatment for 2019-nCoV acute respiratory disease

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1452

OpenAlex

Influential

1155

CrossRef

Cite This

APA Style

                            
                                
                                    Peter J. Richardson, 
                                
                                    Ivan Griffin, 
                                
                                    Catherine Tucker
                                
                                et al.
                            
                            (2020). 
                            Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. 
                            The Lancet
                            , 395
                            (10223)
                            , e30-e31.
                            https://doi.org/10.1016/s0140-6736(20)30304-4
                        

Identifiers

DOI: 10.1016/s0140-6736(20)30304-4
PMID: 32032529
PMCID: PMC7137985

Data Quality

Data completeness: 72%